QR kód

A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study

Abstract Introduction Amlitelimab (SAR445229, KY1005), a nondepleting anti-OX40 ligand monoclonal antibody, reduced lesions and pruritus in phase 2a and 2b trials in adults with moderate-to-severe atopic dermatitis (AD). Here, efficacy and durability of amlitelimab across body regions were evaluated...

Celý popis

Uloženo v:
Hlavní autoři: Adam Reich, Andrew Blauvelt, Stephan Weidinger, Vivian Y. Shi, Norito Katoh, Charles Lynde, Xinghua Gao, Nicole M. Armstrong, Charlotte Bernigaud, Kassim Rahawi
Médium: Artigo
Jazyk:Inglês
Vydáno: Adis, Springer Healthcare 2025-12-01
Edice:Dermatology and Therapy
Témata:
Amlitelimab
Atopic dermatitis
Body region
Eczema Area and Severity Index
Edema
Erythema
On-line přístup:https://doi.org/10.1007/s13555-025-01609-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky